Potential Ascletis Pharma Inc. (HKG:1672) shareholders may wish to note that the Founder, Jinzi Jason Wu, recently bought CN¥3.5m worth of stock, paying CN¥3.05 for each share. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 0.2%.
The Last 12 Months Of Insider Transactions At Ascletis Pharma
Notably, that recent purchase by Jinzi Jason Wu is the biggest insider purchase of Ascletis Pharma shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is HK$3.12. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Ascletis Pharma insider decided to buy shares at close to current prices. Jinzi Jason Wu was the only individual insider to buy over the year.
Jinzi Jason Wu bought 2311000 shares over the last 12 months at an average price of HK$3.02. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership of Ascletis Pharma
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Ascletis Pharma insiders own 53% of the company, worth about HK$1.9b. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
So What Do The Ascletis Pharma Insider Transactions Indicate?
It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. When combined with notable insider ownership, these factors suggest Ascletis Pharma insiders are well aligned, and quite possibly think the share price is too low. One for the watchlist, at least! Of course, the future is what matters most. So if you are interested in Ascletis Pharma, you should check out this free report on analyst forecasts for the company.
Of course Ascletis Pharma may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.